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The purpose of this study was to determine if race is a factor on overall survival when stage at diagnosis is compared.
In this study, a total of 93 women with triple negative breast cancer (TNBC) were evaluated for survival outcomes after
diagnosis between the year 2000 through 2010. Thirty-five patients (38%) were African American (AA), and 58 patients
(62%) were Caucasian. Overall survival rates were estimated using the Kaplan-Meier method and compared between
groups using the log-rank test. Student’s t-test was used to calculate differences in cancer recurrence and mortality
rates by stage and race. Cox proportional hazards ratios were used to determine the association of patient and
variables with clinical outcome. Of women diagnosed with stage 1 breast cancer, the overall survival rates for AAs was
100% compared to Caucasians at 94% (95% CI, 0.003 to 19; P = 0.5). For women with stage 2 breast cancer, overall
survival for AA women was 85% and for Caucasian women was 86% (HR = 0.8; 95% CI, 0.3 to 2.6; P = 0.73). For
advanced stages (stage 3 and 4), survival for AA women were 78% and 40% for Caucasian women (HR = 0.6; 95% CI 0.2
to 1.98; P = 0.43). Rates of recurrence and mortality were not significantly different between AA and Caucasian TNBC
patients. After controlling for patient variables, race was not significantly associated with OS (HR = 1.24; 95% CI, 0.32 to
5.08; P = 0.74) when comparing AA to Caucasian patients. Our study suggests that race does not have an effect on
overall survival in African American and Caucasian women diagnosed with TNBC in Arkansas.
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Breast cancer is a major health problem that is expected to
affect more than 230,000 women in the United States in
2011 (Brawley & Berger 2011). Fortunately, for Arkansas, it
was reported that there was a 9.3% decline in the incidence
of invasive female breast cancer in 2003, and the decline
continued through 2005 (Balamurugan et al. 2009). This
decline in breast cancer incidence was significantly higher
(p < 0.05) among invasive cancers, particularly among
women ages 50 and older and for those having estrogen-* Correspondence: henryrondas@uams.edu
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reproduction in any medium, provided the origreceptor positive tumors (Balamurugan et al. 2009). Al-
though that report is encouraging, it has been reported
that in Arkansas, death rates have increased by 1.9% per
year among AA women since 1975; whereas, the death rate
has declined by 1.6% per year since 1987 among Caucasian
women (DeSantis et al. 2008). This finding is overwhelm-
ing in comparison to all other states, except Mississippi
(DeSantis et al. 2008). These observed differences in death
rates among African American (AA) women may be attrib-
uted to a variety of factors including advanced stage of dis-
ease at the time of diagnosis (Weir et al. 2003), less prompt
access to medical care (Shavers & Brown 2002), and socio-
economic factors (Brawley 2002). Additionally, an aggres-
sive form of breast cancer known as triple negative breast
cancer (TNBC) may be a factor resulting in increased mor-
tality rates among young, pre-menopausal AA women
(Amirikia et al. 2011).ger. This is an open access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
Table 1 Patient characteristics by race











Premenopausal 17 48.6 21 36.2
Postmenopausal 18 51.4 37 63.8
Histology .696
Ductal 33 94.3 50 86.2
Other 2 3.45 8 13.8
Clinical Stage .564
I 7 20.0 16 27.6
II 20 57.1 28 48.2
III 4 11.4 14 24.1
IV 5 14.3 1 1.72
Grade .685
I/II 0 0 8 13.8
III 33 94.3 47 81.0
Unknown 2 5.71 3 5.17
Neo/Adj chemotherapy .121
Yes 30 85.7 45 77.6
No 3 8.57 10 17.2
Unknown 2 5.71 3 5.17
Adjuvant radiotherapy .143
Yes 17 47.2 25 41.7
No 19 52.8 35 58.3
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express the estrogen receptor (ER), progesterone receptor
(PR), or HER-2/neu receptor (Reis-Filho & Tutt 2008). The
lack of receptors has made adequate therapies elusive
(Hudis & Gianni 2011), as conventional chemotherapy and
endocrine therapies are rendered ineffective due to lack of
a therapeutic target. Epidemiological studies provide evi-
dence of significantly higher mortality and prevalence rates
due to TNBC among young, pre-menopausal AA women
(Amirikia et al. 2011; Carey et al. 2006; Tammemagi 2007).
However, there are limited studies that specifically address
the question as to whether race independently is a prog-
nostic factor in predicting survival outcomes in TNBC
patients. Furthermore, to our knowledge, there are no re-
ports in the published literature that assess triple negative
or other types of breast cancer trends in Arkansan women
as it relates to ethnicity, treatment response, cancer recur-
rence and overall clinical outcome. Therefore, this retro-
spective study was undertaken to evaluate the effect of
race on survival outcomes among AA and Caucasian




Institutional review board approval was obtained from
the University of Arkansas for Medical Sciences (UAMS)
prior to commencement of this retrospective study. The
retrospectively maintained database in the Women’s
Oncology Clinic of the Winthrop P. Rockefeller Cancer In-
stitute of UAMS was queried from June 2000 to October
2010 to identify all patients with a diagnosis of stage I-IV
biopsy-proven invasive TNBC who received neoadjuvant
or adjuvant chemotherapy and/or radiotherapy. The final
analysis included 93 patients. Patient variables recorded
included race, menopausal status, tumor characteristics,
stage and grade at diagnosis, presence of residual disease
after treatment, recurrence information and treatment de-
tails including receipt or non-receipt of chemotherapy
and/or radiotherapy. Race information was self-reported
based on data derived from forms completed during the
patient’s initial visit to the clinic.
Staging and pathological assessment
The American Joint Committee on Cancer Criteria (sixth
edition) (Singletary et al. 2003) was used to define the ini-
tial clinical and final pathologic stage of breast cancer pa-
tients. Histologic type and grade were defined according
to the WHO classification system (The World Health
Organization 1982) and modified Black’s nuclear grading
system (Black & Speer 1957), respectively. Breast pathol-
ogists at UAMS reviewed all pathologic breast specimens
and invasive carcinomas were confirmed on initial core
biopsy specimens. In our study, we defined pathologiccomplete response (pCR) as the absence of invasive can-
cer in both the breast and axillary lymph nodes on final
pathologic assessment. All surgical breast and axillary
lymph node specimens were reviewed to identify the pres-
ence or absence of residual invasive and in situ disease.
Pathologic diagnosis and determination of hormone
receptor status was determined using standard immuno-
histochemical methods. Tumors with less than 1% nuclear
staining were considered to have a negative status for ER
and/or PR. HER-2/neu receptor status was assessed by im-
munohistochemistry only if the results were 0/1+ or 3+
staining and by fluorescence in situ hybridization (FISH)
confirmation if 2+ immunohistochemistry staining was
present.
Statistical analyses
Race was divided into the following two groups: AA and
Caucasian female patients. Because of the small number
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2 tumors were grouped together.
Patient’s race and tumor characteristics were compared
across groups with the Chi-square test or Wilcoxon rank
sum test, as appropriate. Overall survival (OS) was defined
as the time from initiation of chemotherapy or surgery to
date of death due to any cause or date of last follow-up.
Recurrence free-survival (RFS) was measured from the
date of definitive surgery to the date of first documented
recurrence (local or distant) or date of last follow-up. Pa-
tients who died before experiencing a disease recurrence
were censored at their date of death in the analysis of RFS.
Survival outcomes were estimated using the Kaplan-Meier
product-limit method and compared between groups using
the log-rank statistic. Student’s t-test was used to calculate
differences in cancer recurrence and mortality rates by
stage and race. We fitted Cox proportional hazards models
for each survival outcome to determine the simulta-
neous relationship of patient and tumor variables with
each outcome. For each outcome, pCR and clinicalFigure 1 Overall survival (OS) months after diagnosis by race and/or
TNBC, c) OS by race in stage III TNBC d) OS by race in stage IV TNBC e) OSstage achieved statistical significance by the likelihood
ratio test and were included in the Cox model. All
statistical analyses were performed using GraphPad Prism,
version 4 software (La Jolla, CA). For all of the statistical




Between June 2000 and October 2010, 93 patients diag-
nosed with stage I-IV TNBC and treated at UAMS in Little
Rock, Arkansas were included in this report. Table 1 sum-
marizes the characteristics of the 93 patients included in
this report.
Of the 93 patients, 35 patients (38%) were AA, and 58
patients (62%) were Caucasian. Median age at diagnosis
was 50 years (range, 26 to 76 years) among AA patients
and 53 years (range, 30 to 82 years) among Caucasian
patients. There was no significant association between
menopausal status and race (P = 0.232). Overall clinicalstage of TNBC. a) OS by race in stage I TNBC, b) OS by race in stage II
by race in stage I-IV TNBC f) OS by stage of TNBC.
Table 2 Cancer recurrence rates by stage and race among
African American (AA) and Caucasian women after








Stage I 2 4 6 0.56
Stage II 7 10 17 0.45
Stage III 2 6 8 0.95
Stage IV 2 1 3 -
Total 13 (37%) 21 (36%) 34 (37%)
Percentages represent the total number of patients per group divided by the
total number of patients by race in the study (n) × 100.
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ent between races (Stage: P = 0.564; Grade: P = 0.685).
The majority of patients were diagnosed with clinical stage
I/II (76%) TNBC and had grade 3 breast cancer (86%).
Both stage and grade were similar between races. Invasive
ductal carcinomas were the predominant histologic type of
cancer among both AAs (94%) and Caucasian (86%) pa-
tients. Of the 93 patients, 75 (81%) received adjuvant
chemotherapy and 41 (44%) received adjuvant radiother-
apy. The majority of TNBC patients either received an
anthracycline-based chemotherapy regimen with a taxane
(26%) or with fluorouracil (27%) which was not signifi-
cantly different between the two races (63% of AA patients
versus 53% of Caucasian patients, P = 0.06)(not shown).
Overall survival
Of the 93 TNBC patients, 80 patients (86%) were ei-
ther alive or lost to follow-up at the end of our study.
Figure 1a-f illustrate the Kaplan-Meier survival curves
with the corresponding log-rank P-values for OS by race
and stage of breast disease. Of women diagnosed with
stage I breast cancer, the OS rates for AAs was 100% com-
pared to Caucasians at 94% (95% CI, 0.003 to 19; P = 0.54)
(Figure 1a). For women with stage II breast cancer, OS forFigure 2 Rate of breast cancer recurrence months after surgery by raAA women was 85% and for Caucasian women was 86%
(HR = 0.8; 95% CI, 0.3 to 2.6; P = 0.73) (Figure 1b). For ad-
vanced stages (stage III and IV), survival for AA women
were 78% and 40% for Caucasian women (HR = 0.6; 95%
CI 0.2 to 1.98; P = 0.43) (Figure 1c and d). Collectively, our
results demonstrate that differences in OS due to race and
overall stage of breast disease between the two races are
not statistically significant (Figure 1e and f).
Cancer recurrence and mortality
Cancer recurrence rates was determined by stage and
race among AA and Caucasian TNBC patients following
surgery from the year 2000 to 2010 (Table 2). Of a total
of 23 stage I TNBC patients, 2 AA (9%) and 4 Caucasian
patients (17%) experienced a recurrence. The majority of
TNBC patients who experienced a recurrence from the
disease had stage II TNBC (n = 17). Of a total of 48 stage
II TNBC patients, 7 AAs (15%) and 10 Caucasians (21%)
experienced cancer recurrence. Of the 18 stages III breast
cancer patients, a total of 2 AA (11%) and 6 Caucasian
(33%) women experienced a recurrence from an initial
diagnosis of breast cancer. There was no significant dif-
ference in cancer recurrence rates between the two races
(P = 0.25) (Figure 2).
Mortality rate was also determined by stage and race
among AA and Caucasian TNBC patients from the year
2000 to 2010 (Table 3). Similar to recurrence, mor-
tality rates did not differ significantly between the two
races when stage of disease was considered (P = 0.71)
(Figure 3).
Cox proportional hazard modeling
Table 4 illustrates patient variables that were fitted to
the Cox proportional hazard model to determine sur-
vival outcome. When comparing AA versus Caucasian
TNBC patients and controlling for patient and tumor
characteristics, race was not significantly associated with
OS (HR = 1.24; 95% CI, 0.32 to 5.08; P = 0.74). Patientsce.
Table 4 Multiple variable cox proportional hazard models
Overall survival
Variable HR 95% CI P
Caucasian vs. AA 1.24 0.32 to 5.08 0.74
pCR: yes vs. no 0.16 0.06 to 0.41 0.0002
Clinical Stage: I/II vs. III/IV 0.10 0.01 to 0.13 <0.0001
Premenopausal vs. Postmenopausal 1.30 0.44 to 3.93 0.24
XRT vs. No XRT 0.47 0.17 to 1.42 0.19
Chemo v. No Chemo 0.81 0.20 to 3.36 0.78
Abbreviations: pCR pathologic complete response, XRT radiotherapy; Chemo
chemotherapy.
Table 3 Mortality rate by stage and race among African
American (AA) and Caucasian women after diagnosis








Stage I 0 1 1 -
Stage II 3 4 7 0.09
Stage III 1 8 9 -
Stage IV 1 1 2 -
Total 5 (14%) 14 (24%) 19 (20%)
Percentages represent the total number of patients per group divided by the
total number of patients by race in the study (n) × 100.
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of death (HR = 0.16; 95% CI, 0.06 to 0.41; P = 0.0002)
compared to patients who did not achieve a pCR. Similarly,
patients who had earlier stage of TNBC had significantly
better OS (HR = 0.10; 95%CI, 0.01 to 0.13; P < 0.0001).Discussion
Breast cancer is the most prevalent malignancy and the
second leading cause of cancer death among women in
the United-States (DeSantis et al. 2011). It is well docu-
mented that breast cancer incidence is higher among
Caucasian women, compared to other ethnic groups
(DeSantis et al. 2011). However, several studies have
noted an increased incidence, late stage at diagnosis, and
poorer survival outcome among young, AA women of
childbearing age diagnosed with TNBC (Stead et al. 2009;
Anderson et al. 2008; Tawfik et al. 2010). TNBC is char-
acterized by a lack of ER, PR, and HER-2/neu receptors
and an aggressive, basal-like phenotype that is most
prevalent among AA women (Ray & Polit 2010). The in-
creased incidence and mortality rates in AA vs. Caucasian
TNBC patients may be multifactorial, including advanced
stage of disease at the time of diagnosis (Weir et al. 2003),Figure 3 Rate of mortality months after diagnosis by race.less prompt access to medical care (Shavers & Brown
2002), and socioeconomic factors (Brawley 2002).
There are limited studies that address the issue of race
and survival for women with TNBC. In one large cohort
study, consisting of 6370 women identified as having
triple-negative breast cancer, women with triple-negative
breast cancers were significantly more likely to be non-
Hispanic black (odds ratio = 1.77), under the age of 40
(odds ratio [OR], 1.53), and had worse survival, with a
5-year relative survival of only 14% (Bauer et al. 2007).
Similarly, a study by Stead et al. reported that the odds
of having a triple negative tumor were 3-fold higher
(HR = 5.5, 95% CI 1.6, P = 0.0001) in black compared
with white women (Stead et al. 2009). Contrary to these
studies, our study demonstrates for the first time that
there is no significant difference in OS between AA and
Caucasian TNBC patients treated at the UAMS Women’s
Oncology Clinic in Arkansas (HR = 1.24; 95% CI, 0.32 to
5.08; P = 0.74). An interesting observation in our cohort
is the age and menopausal status of our patients, with
65% being postmenopausal and over half of the patients
being age 50 or older at diagnosis, which is contrary to
the previously observed association between TNBC and
younger age and premenopausal status (Anderson et al.
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is no significant difference in the likelihood of receiving
adjuvant chemotherapy and radiotherapy by race. Due to
the retrospective nature of our study and the limitation
of our small patient population size, which may account
for the non-significant differences between race and sur-
vival outcomes, no power calculations were performed.
However, our cohort, like MD Anderson’s, represents a
geographically uniform group of TNBC patients with
similar socioeconomic and cultural risks treated with a
similar multidisciplinary approach at UAMS in Little
Rock, Arkansas. In that study reported by Dawood et al.,
470 patients with TNBC were treated with primary sys-
temic chemotherapy at the MD Anderson Cancer Center.
Their results demonstrated that race does not signifi-
cantly affect pCR rates or survival outcomes in women
with TN breast cancer (Dawood et al. 2009). In addition,
the authors found that the 3-year OS rate was similar be-
tween 100 black patients (68%) and 371 white/other race
(62%) patients who received the same treatment condi-
tions (P = 0.091). Further, RFS (HR = 1.08; 95% CI, 0.69 to
1.68; P = 0.747) and OS (HR = 1.08; 95% CI, 0.69 to 1.68;
P = 0.735) was similar between the two races even after
controlling for patient and tumor characteristics. If there
is no significant difference between AAs and Caucasians
in response to traditional cytotoxics, is it possible that a
difference by race might exist in response to biologic
agents? We conducted a small prospective phase II study
using standard chemotherapy and bevacizumab in the
neoadjuvant setting for locally advanced or operable
breast cancer at UAMS. AAs had 75% pCR (9/12),
whereas Whites had only 28% pCR (7/25; P = 0.0069),
possibly in part because 100% of AA (12/12) had ductal
carcinoma compared with only 64% (16/25) of Whites
(P = 0.017). Further evaluation of this question is needed
to address this issue (Makhoul et al. 2013).
In conclusion, to our knowledge, this is the only retro-
spective study that details TNBC trends in patients from
Arkansas as it relates to race, stage of breast disease at
diagnosis, recurrence and mortality, and overall survival.
Our study provides supporting evidence that race is not
a contributing factor on cancer recurrence, mortality or
survival in AA and Caucasian TNBC patients. Future
prospective studies, with participation from larger insti-
tutions that are represented by a diverse breast cancer
population, will be necessary to increase statistical power
and to clearly define whether or not race affects clinical
outcomes in patients with TNBC.Abbreviations
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